Related Experiment Videos
[Alpha-interferon therapy in Crohn's disease: initial clinical results]
H P Wirth1, G Zala, C Meyenberger
1Department für Innere Medizin, Universitätsspital Zürich.
Schweizerische Medizinische Wochenschrift
|July 13, 1993
Summary
Interferon alpha-2b showed potential in treating steroid-dependent Crohn's disease, with some patients experiencing significant symptom reduction. Further research is needed to define its role in inflammatory bowel disease management.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Crohn's disease is a chronic inflammatory bowel disease (IBD) often requiring long-term steroid treatment.
- Steroid-dependent Crohn's disease presents challenges due to potential side effects and refractory disease states.
Observation:
- This study describes four interferon alpha-2b therapies in three patients with steroid-dependent Crohn's disease.
- Interferon alpha-2b was administered over 24 weeks, with a stepwise reduction of concomitant prednisolone dosage.
- Disease activity was assessed using the Crohn's Disease Activity Index (CDAI).
Findings:
- Two of the four treatment courses showed no response, necessitating early cessation due to increased disease activity.
- The other two treatments resulted in significant reductions in CDAI scores (118 and 70 units) within 8 weeks.
- One patient experienced a remarkable improvement, with complete resolution of extraintestinal manifestations and sustained CDAI amelioration for 30 weeks, allowing 18 weeks of steroid-free treatment.
Implications:
- Interferon alpha-2b may help overcome steroid-refractory states in Crohn's disease.
- Preliminary observations suggest a potentially more favorable response in female patients.
- More extensive research is required to establish the definitive role and optimal use of interferon in managing IBD.